Fredag 20 November | 21:34:30 Europe / Stockholm
Est. tid*
2027-02-25 08:45 Bokslutskommuniké 2026
2026-11-12 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-05-27 - X-dag ordinarie utdelning ALZ 0.00 SEK
2026-05-26 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-03-25 - Bokslutskommuniké 2025
2025-11-13 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning ALZ 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-03-07 - Extra Bolagsstämma 2025
2025-02-27 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning ALZ 0.00 SEK
2024-05-29 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-02-28 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-30 - Årsstämma
2023-05-25 - X-dag ordinarie utdelning ALZ 0.00 SEK
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2022-05-19 - Kvartalsrapport 2022-Q1
2022-05-18 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2021-05-19 - Kvartalsrapport 2021-Q1
2021-05-18 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2020-05-15 - Kvartalsrapport 2020-Q1
2020-05-14 - Årsstämma
2020-02-27 - Extra Bolagsstämma 2020
2020-02-26 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning ALZ 0.00 SEK
2019-05-17 - Kvartalsrapport 2019-Q1
2019-05-16 - Årsstämma
2019-02-26 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2018-05-18 - Kvartalsrapport 2018-Q1
2018-05-17 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-05-18 - X-dag ordinarie utdelning ALZ 0.00 SEK
2017-05-17 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-28 - Kvartalsrapport 2016-Q3
2016-08-29 - Kvartalsrapport 2016-Q2
2016-05-19 - X-dag ordinarie utdelning ALZ 0.00 SEK
2016-05-18 - Årsstämma
2016-05-18 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Alzinova är ett bioteknikbolag. Bolaget är specialiserat inom terapeutiskt behandling av Alzheimers och bedriver forskning och utveckling av peptider som vidareutvecklas som vaccin. Utöver det utvecklar bolaget även diverse forskningsverktyg inom arbetsområdet. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades år 2011 och har sitt huvudkontor i Mölndal.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Alzinova plans a blinded twelve-month interim analysis and a separate futility analysis in ADVANCE

2026-11-19 08:52:00

Alzinova AB (“Alzinova” or the “Company”) today announces the planned interim analyses in the Company's Phase 2a study ADVANCE (ALZ-C-002) of its therapeutic vaccine ALZ-101 in early Alzheimer's disease. The plan comprises a twelve-month blinded interim analysis and a separate non-binding futility analysis. The planned analyses have been discussed with the Company's expert panel, including Professor Marwan Sabbagh, Global Principal Investigator for the ADVANCE study.

Twelve-month blinded interim analysis
When half of participants have completed the Week 52 assessment, a blinded interim analysis is planned. It will assess biomarkers and clinical measures at Week 52, including plasma phosphorylated tau-217 (p-tau217) and the Alzheimer's Disease Composite Score (ADCOMS). As the analysis will be performed on pooled data, without revealing treatment assignment, it is intended to provide an early indication of biomarker activity and clinical effect alongside safety and tolerability while maintaining the integrity of the ongoing study. Subject to enrolment, and study progression, this analysis is currently expected to be reportable around the third quarter of 2028.

Non-binding futility analysis
A non-binding futility analysis is planned for the third quarter of 2028, at the same timepoint as the twelve-month interim analysis, once approximately 50% of participants have completed the Week 52 assessment of the primary endpoint. It will be performed by independent, unblinded statisticians.

The futility analysis is designed to assess whether the available interim data support continuation of the study towards its final analysis. It is a safeguard and designed to recommend stopping the study only if the interim data make it unlikely that the primary endpoint will be met at the final analysis. As the analysis is non-binding, any recommendation will form part of the overall assessment of the study and will not in itself require the Company to stop the trial. As previously communicated, results from ADVANCE are anticipated in late 2029.

Professor Marwan Sabbagh, Global Principal Investigator for the ADVANCE study, comments:
“I have spent a good part of my career watching Alzheimer’s programmes wait years for a single cognitive readout and then discover that the biology was already telling us something. That is no longer an acceptable way to run a Phase 2a study. A blinded interim look at biomarkers and clinical effect, including p-tau217 and ADCOMS, while an independent group tests whether the study is futile, is the right use of an interim. It will tell us, much earlier than 2029, whether this programme deserves the time, the participants and the capital required to finish the study.”

About the ADVANCE study
ADVANCE is a randomised, double-blind, placebo-controlled Phase 2a study evaluating the clinical activity, safety, tolerability, immunogenicity and biomarker effects of ALZ-101 in approximately 120 participants aged 50–85 years with early Alzheimer's disease, defined as mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease according to NIA-AA criteria. The primary endpoint is the effect of ALZ-101 versus placebo on clinical progression, measured as change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) through Week 52. The study is being conducted in the United States, the European Union and the United Kingdom. Results are anticipated in late 2029.

About ALZ-101
ALZ-101 is Alzinova's lead candidate, a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers believed to be central to the onset and development of the disease with great accuracy. ALZ-101 has received Fast Track designation from the US FDA.

For further information, please contact:
Tord Labuda, CEO
E-mail: IR@alzinova.com

About Alzinova
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, with a focus on targeting toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million people affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, as well as the diagnostic project ALZ-401, which aims to develop a blood test to identify an increased risk of Alzheimer's disease before symptoms appear. The goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com